WALL STREET PAYDAY: 4 banks made a killing from Monday's $20 billion in biotech deals

Scott Olson/Getty Images

Two major biotech acquisitions dropped on Monday: French drugmaker Sanofi spent $US11.6 billion to buy US hemophilia firm Bioverativ, and Celgene spent $US9 billion on cancer specialist Juno Therapeutics.

The more than $US20 billion in pharma mergers and acquisitions means a windfall of as much as $US185 million in fees for four investment banks, with JPMorgan raking in the most from the deals.

JPMorgan will split $US45 million to $US55 million in fees with Guggenheim Partners for advising Bioverativ, while Lazard will take in $US30 million to $US40 million for advising Sanofi, according to Jeffrey Nassof, the director of the consulting firm Freeman & Co.

JPMorgan also advised on the Celgene-Juno tieup, earning $US25 million to $US35 million in fees for advising Celgene. Morgan Stanley stands to make $US45 million to $US55 million for advising Juno.

M&A activity is off to a blistering start for the sector in 2018 – Celgene earlier this month also spent as much as $US7 billion to buy Impact Biomedicines – and Monday’s deals could be a “sign that large-cap Pharma’s getting more aggressive again with dealmaking,” according to Nassof.

There were only nine US pharma acquisitions of $US5 billion or more announced in 2017, compared with 14 in 2016 and 23 in 2015, Nassof said.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.